Compare
Cardio Diagnostics Holdings, Inc. vs Celldex Therapeutics, Inc. vs Insight Molecular Diagnostics Inc. vs Biomerica Inc
| Latest fiscal year | Cardio Diagnostics Holdings, Inc. CDIO | Celldex Therapeutics, Inc. CLDX | Insight Molecular Diagnostics Inc. IMDX | Biomerica Inc BMRA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-05-31 |
| Revenue | $14.8K | $1.54M | $4.05M | $4.45M |
| Revenue growth (YoY) | -57.5% | -78.0% | +115.6% | -16.2% |
| Gross margin | n/a | 87.1% (computed) | 56.7% | 8.1% |
| Operating margin | n/m | n/m | n/m | -119.5% |
| Net margin | n/m | n/m | n/m | -84.8% |
| Net income | -$6.50M | -$258.76M | -$50.22M | -$3.77M |
| EPS (Diluted) | -$3.71 | -$3.90 | -$1.65 | -$1.30 |
| Operating cash flow | -$5.73M | -$210.94M | -$22.18M | -$3.42M |
| Free cash flow | -$5.91M | -$213.66M | -$25.37M | n/a |
| Cash & equivalents | $0 | $28.87M | $11.58M | $1.31M |
| Total assets | $7.77M | $582.98M | $25.76M | $6.76M |
| Total liabilities | $793.1K | $55.82M | $57.22M | $4.13M |
| Shareholders' equity | $6.97M | $527.16M | -$31.46M | $2.63M |
| Return on year-end equity | -93.2% | -49.1% | n/a | -143.5% |
| Shares outstanding | 1.83M | 66.55M | 28.68M | 3.20M |
Revenue, most recent five fiscal years
| Fiscal year | Cardio Diagnostics Holdings, Inc. | Celldex Therapeutics, Inc. | Insight Molecular Diagnostics Inc. | Biomerica Inc |
|---|---|---|---|---|
| Latest | $14.8K Ended 2025-12-31 | $1.54M Ended 2025-12-31 | $4.05M Ended 2025-12-31 | $4.45M Ended 2026-05-31 |
| 1 year earlier | $34.9K Ended 2024-12-31 | $7.02M Ended 2024-12-31 | $1.88M Ended 2024-12-31 | $5.31M Ended 2025-05-31 |
| 2 years earlier | $17.1K Ended 2023-12-31 | $6.88M Ended 2023-12-31 | $1.50M Ended 2023-12-31 | $5.42M Ended 2024-05-31 |
| 3 years earlier | $950 Ended 2022-12-31 | $2.36M Ended 2022-12-31 | $958.0K Ended 2022-12-31 | $5.34M Ended 2023-05-31 |
| 4 years earlier | $901 Ended 2021-12-31 | $4.65M Ended 2021-12-31 | $2.20M Ended 2021-12-31 | $18.87M Ended 2022-05-31 |